Save Product
Product Details
Application
Synonyms
MS4A1, CD20, MS4A-1
Source
Nanodisc Human CD20 Full Length, His Tag (CD0-H52H1) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).
Predicted N-terminus: Met 1
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 35.2 kDa | 24.7 kDa. The protein migrates as 25 kDa and 40 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
*The isotype control of empty/mock nanodisc (Cat. No. APO-H51H3) is sold separately and not included in protein, you can follow the link for product information.
Structure
Nanodisc membrane protein is wrapped by a synthetic phospholipid bilayer membrane structure, composed of membrane scaffold proteins (MSPs) and phospholipids.
Synthesis Process
Nanodisc reconstitution is a self-assembly process that starts from purified, detergent-solubilized membrane proteins and reconstitutes them into synthetic phospholipid bilayers stabilized by MSP1D1 membrane scaffold protein. This creates a stable, detergent-free environment that preserves native conformation and biological activity, with excellent homogeneity and full compatibility with cell-based assays such as FACS and binding assays in antibody discovery and screening (ELISA),etc.
Purity
>85% as determined by SDS-PAGE.
Formulation
Supplied as 0.2 μm filtered solution in 20 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Shipping and Storage
This product is supplied and shipped on dry ice.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 6 months under sterile conditions.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human CD20 Full Length, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 85% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA
Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag (Cat. No. CD0-H52H1) with a linear range of 1-63 ng/mL (QC tested).
Protocol
Immobilized Human CD20 Full Length, His Tag (Cat. No. CD0-H52H1) at 5 μg/mL (100 μL/well) can bind Biosimilar of Obinutuzumab with a linear range of 0.3-5 ng/mL (Routinely tested).
Protocol
Bioactivity-TR-FRET
In this TR-FRET assay, Monoclonal Anti-His Tag Antibody Europium chelate (for TR-FRET) (Cat. No. FRT-TD05) is used as the Donor and Monoclonal Anti-Mouse IgG Antibody FA-Labeled (for TR-FRET) (Cat. No. FRT-TA03) is used as the Acceptor. Human CD20 Full Length, His Tag (Cat. No. CD0-H52H1), at 5 ng/well and Human CD3 epsilon, Mouse IgG2a Fc Tag (Cat. No. CDN-H5253), at 2.5 ng/well, can bind to the Glofitamab with a linear detection range of 16-0.008 μg/mL (Routinely tested).
Bioactivity-SPR
Human CD20 Full Length, His Tag (Cat. No. CD0-H52H1) captured on CM5 Chip via anti-His antibody can bind Rituximab with an affinity constant of 52.7 nM as determined in SPR assay ( Biacore T200) (Routinely tested).
Protocol
Bioactivity-BLI
Loaded Rituximab on Protein A Biosensor, can bind with Human CD20 Full Length, His Tag (Cat. No. CD0-H52H1) an affinity constant of 12.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Bioactivity-FACS
2e5 of CD20-CAR-293 cells transfected with anti-CD20-scFv were stained with 100 μL of 3 μg/mL of Human CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc) (HEK293)(Cat. No. CD0-H52H1) and negative control protein respectively, washed and then followed by PE anti-His antibody and analyzed with FACS (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
B-lymphocyte antigen CD20
- Category：
- Approved Drugs：
35 Details
- Drugs in Clinical Trials：
132 Details
- Highest Development Stage：
Approved
Contact Us
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
Drug Candidate Licensing
